Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects

American Heart Journal

Volumn 163, Issue 6, 2012, Pages 912-930

  Garnett, Christine E ^a   Zhu, Hao ^a   Malik, Marek ^b   Fossa, Anthony A ^c   Zhang, Joanne ^a   Badilini, Fabio ^d   Li, Jianguo ^e   Darpö, Börje ^f   Sager, Philip ^g   Rodriguez, Ignacio ^h  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ICardiac Technologies   (United States)

^d AMPS ^*  (Italy)

^e ASTRAZENECA   (United Kingdom)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g Sager Consulting Partners   (United States)

^h HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

BODY POSTURE; CONTROLLED STUDY; DRUG EXPOSURE; ELECTROCARDIOGRAM; HEALTH CARE POLICY; HEART DISEASE; HEART RATE VARIABILITY; HEART REPOLARIZATION; HUMAN; HYSTERESIS; INFORMATION PROCESSING; MEDICAL ASSESSMENT; METHODOLOGY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REST; REVIEW; RISK; STUDY DESIGN;

AUTONOMIC NERVOUS SYSTEM; CARDIAC PACING, ARTIFICIAL; ELECTROCARDIOGRAPHY, AMBULATORY; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS;

EID: 84862521911     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.02.023     Document Type: Review

References (87)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22. (Pubitemid 38269278)
2. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72. (Pubitemid 37311108)
3. Tornoe CW, Garnett CE, Wang Y, et al. Creation of a knowledge management system for QT analyses. J Clin Pharmacol 2010:1035-42.
4. Arrowood JA, Kline J, Simpson PM, et al. Modulation of the QT interval: effects of graded exercise and reflex cardiovascular stimulation. J Appl Physiol 1993;75:2217-23. (Pubitemid 23352399)
5. Bazett JC. An analysis of time relations of electrocardiograms. Heart 1920;7:353-67.
6. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920;53:469-86.
7. Hodges M, Salerno D, Erlien D. Bazett QT correction reviewed-evidence that a linear QT correction for heart-rate is better. J Am Coll Cardiol 1983;1:694.
8. Karjalainen J, Viitasalo M, Manttari M, et al. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 1994;23:1547-53. (Pubitemid 24182117)
9. Kawataki M, Kashima T, Toda H, et al. Relation between QT interval and heart rate. applications and limitations of Bazett's formula. J Electrocardiol 1984;17:371-5. (Pubitemid 15200598)
10. Larsen K, Skulason Th. Det normale Elektrocardiogram. I. Analyse af Ekstremitetsafledningerne hos 100 sunde Mennesker I Alderen fra 30 til 50 Aar. Nord Med 1941;9:350-8.
11. Rautaharju PM, Warren JW, Calhoun HP. Estimation of QT prolongation. A persistent, avoidable error in computer electrocardiography. J Electrocardiol 1990;23(Suppl):111-7.
12. Rickards AF, Norman J. Relation between QT interval and heart rate. New design of physiologically adaptive cardiac pacemaker. Br Heart J 1981;45:56-61. (Pubitemid 11168842)
13. Sagie A, Larson MG, Goldberg RJ, et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797-801.
14. Sarma JS, Sarma RJ, Bilitch M, et al. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: reevaluation of Bazett's formula. Am J Cardiol 1984;54:103-8. (Pubitemid 14085358)
15. Schlamowitz I. An analysis of the time relationships within the cardiac cycle in electrocardiograms of normal men. I. The duration of the Q-T interval and its relationship to the cycle length (R-R interval). Am Heart J 1946;31:329.
16. Wohlfart B, Pahlm O. Normal values for QT intervals in ECG during ramp exercise on bicycle. Clin Physiol 1994;14:371-7. (Pubitemid 24217666)
17. Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002;282:H2356-63. (Pubitemid 34663047)
18. Zhang J, Machado SG. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat 2008;18:451-67. (Pubitemid 351891689)
19. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 2002;25:209-16.
20. Franz MR, Swerdlow CD, Liem LB, et al. Cycle length dependence of human action potential duration in vivo. Effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest 1988;82:972-9.
21. Lau CP, Freedman AR, Fleming S, et al. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res 1988;22:67-72. (Pubitemid 18034779)
22. Malik M, Hnatkova K, Novotny T, et al. Subject-specific profiles of QT/RR hysteresis. Am J Physiol Heart Circ Physiol 2008;295:H2356-63.
23. Pueyo E, Smetana P, Caminal P, et al. Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. IEEE Trans Biomed Eng 2004;51:1511-20. (Pubitemid 39100224)
24. Sager PT, Koh SW, Nguyen T. Beta-adrenergic stimulation accelerates human action-potential accommodation. Circulation 1995;92:3499.
25. Malik M, Garnett CE, Zhang J, et al. Studies: questions and quandaries. Drug Saf 2010;33:1-14.
26. Malik M. Assessment of drug-induced QT prolongation: to bin or not to bin? Clin Pharmacol Ther 2005;77:241-6. (Pubitemid 40470380)
27. Ng GA, Brack KE, Patel VH, et al. Autonomic modulation of electrical restitution, alternans and ventricular fibrillation initiation in the isolated heart. Cardiovasc Res 2007;73:750-60. (Pubitemid 46227349)
28. Sager PT. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br J Pharmacol 2008;154:1544-9.
29. Davidowski TA, Wolf S. The QT interval during reflex cardiovascular adaptation. Circulation 1984;69:22-5. (Pubitemid 14215857)
30. Valensi PE, Johnson NB, Maison-Blanche P, et al. Influence of cardiac autonomic neuropathy on heart rate dependence of ventricular repolarization in diabetic patients. Diabetes Care 2002;25:918-23. (Pubitemid 41094293)
31. Saul JP, Arai Y, Berger RD, et al. Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol 1988;61:1292-9.
32. Agelink MW, Boz C, Ullrich H, et al. Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment. Psychiatry Res 2002;113:139-49. (Pubitemid 35447731)
33. Browne KF, Prystowsky E, Heger JJ, et al. Prolongation of the Q-T interval in man during sleep. Am J Cardiol 1983;52:55-9. (Pubitemid 13061326)
34. Nagy D, DeMeersman R, Gallagher D, et al. QTc interval (cardiac repolarization): lengthening after meals. Obes Res 1997;5:531-7. (Pubitemid 127702674)
35. Ahnve S, Vallin H. Influence of heart rate and inhibition of autonomic tone on the QT interval. Circulation 1982;65:435-9. (Pubitemid 12168343)
36. Browne KF, Zipes DP, Heger JJ, et al. The influence of the autonomic nervous-system on QT interval. Am J Cardiol 1982;49:898.
37. Zabel M, Franz MR, Klingenheben T, et al. Rate-dependence of QT dispersion and the QT interval: comparison of atrial pacing and exercise testing. J Am Coll Cardiol 2000;36:1654-8.
38. Magnano AR, Talathoti N, Hallur R, et al. Sympathomimetic infusion and cardiac repolarization: the normative effects of epinephrine and isoproterenol in healthy subjects. J Cardiovasc Electrophysiol 2006;17:983-9.
39. Taggart P, Sutton P, Chalabi Z, et al. Effect of adrenergic stimulation on action potential duration restitution in humans. Circulation 2003;107:285-9. (Pubitemid 36135225)
40. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation 2006;113:1385-92. (Pubitemid 43739434)
41. Magnano AR, Holleran S, Ramakrishnan R, et al. Autonomic nervous system influences on QT interval in normal subjects. J Am Coll Cardiol 2002;39:1820-6. (Pubitemid 34595295)
42. Malik M, Andreas JO, Hnatkova K, et al. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 2008;84:595-603.
43. Malik M, Hnatkova K, Ford J, et al. Near-thorough QT study as part of a first-in-man study. J Clin Pharmacol 2008;48:1146-57.
44. Malik M, Hnatkova K, Schmidt A, et al. Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability. Heart Rhythm 2008;5:1424-31.
45. Malik M, Hnatkova K, Sisakova M, et al. Subject-specific heart rate dependency of electrocardiographic QT, PQ, and QRS intervals. J Electrocardiol 2008;41:491-7.
46. Malik M, Farbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002;87:220-8. (Pubitemid 34177674)
47. Milliez P, Leenhardt A, Maisonblanche P, et al. Usefulness of ventricular repolarization dynamicity in predicting arrhythmic deaths in patients with ischemic cardiomyopathy (from the European Myocardial Infarct Amiodarone Trial). Am J Cardiol 2005;95:821-6. (Pubitemid 40386791)
48. Badilini F, Maison-Blanche P, Childers R, et al. QT interval analysis on ambulatory electrocardiogram recordings: a selective beat averaging approach. Med Biol Eng Comput 1999;37:71-9.
49. Extramiana F, Maison-Blanche P, Haggui A, et al. Control of rapid heart rate changes for electrocardiographic analysis: implications for thorough QT studies. Clin Cardiol 2006;29:534-9. (Pubitemid 44914781)
50. Extramiana F, Maison-Blanche P, Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther 2005;77:247-58. (Pubitemid 40470381)
51. Couderc JP, Vaglio M, Xia X, et al. Impaired T-amplitude adaptation to heart rate characterizes I(Kr) inhibition in the congenital and acquired forms of the long QT syndrome. J Cardiovasc Electrophysiol 2007;18:1299-305. (Pubitemid 350115782)
52. Holzgrefe HH, Cavero I, Gleason CR. Analysis of the nonclinical telemetered ECG: impact of logging rate and RR bin width in the dog and cynomolgus monkey. J Pharmacol Toxicol Methods 2007;56:34-42. (Pubitemid 46829927)
53. Fossa AA, Wisialowski T, Magnano A, et al. Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 2005;312:1-11. (Pubitemid 40096446)
54. Fossa AA, Zhou MJ. Assessing QT prolongation and electrocardiography restitution using a beat-to-beat method. Cardiol J 2010;17:230-43.
55. Crimin KS, Emerson JW, Muirhead RJ. Reference regions for beat-tobeat ECG data. Pharm Stat 2010:162-8.
56. Fossa AA, Wisialowski T, Crimin K, et al. Analyses of dynamic beatto- beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol. Ann Noninvasive Electrocardiol 2007;12:338-48. (Pubitemid 350013256)
57. Newbold P, Sanders N, Reele SB. Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval. Br J Clin Pharmacol 2007;63:279-87.
58. Dmitrienko A, Smith BP. Analysis of the QT interval in clinical trials. Drug Info J 2002;36:269-79.
59. Dmitrienko A, Smith B. Repeated-measures models in the analysis of QT interval. Pharm Stat 2003;2:175-90.
60. Ma HJ, Smith B, Dmitrienko A. Statistical analysis methods for QT/QTc prolongation. J Biopharm Stat 2008;18:553-63. (Pubitemid 351891694)
61. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005;7:E609-24.
62. Rohatagi S, Carrothers TJ, Kuwabara-Wagg J, et al. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. J Clin Pharmacol 2009;49:1284-96.
63. Li J. Evaluation of a drug induced-QT/QTc prolongation in the presence of the drug induced changes in heart rate by using population PK/PD modeling approach: sibenadet experience. Clin Pharmacol Ther 2008;83(S4]).
64. Valentin JP, Amrani AI, El Barnard S, et al. Saturday, 7 July: posters. Fundam Clin Pharmacol 2001;15:12.
65. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008;48:13-8. (Pubitemid 350292272)
66. Connolly SJ, Kates RE, Lebsack CS, et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 1983;52:1208-13. (Pubitemid 14243974)
67. Olsson SB, Edvardsson N, Newell PA, et al. Effect of pentisomide (CM 7857) on myocardial excitation, conduction, repolarization, and refractoriness. An electrophysiological study in humans. J Cardiovasc Pharmacol 1991;18:849-54.
68. Milne JR, Hellestrand KJ, Bexton RS, et al. Class 1 antiarrhythmic drugs-characteristic electrocardiographic differences when assessed by atrial and ventricular pacing. Eur Heart J 1984;5:99-107. (Pubitemid 14161449)
69. Sedgwick ML, Dalrymple I, Rae AP, et al. Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Eur Heart J 1995;16:1641-6. (Pubitemid 26037798)
70. Darpo B, Almgren O, Bergstrand R, et al. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal atrial stimulation. J Cardiovasc Pharmacol 1995;25:681-90.
71. Toivonen L, Viitasalo M, Sundberg S, et al. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000;35:664-9. (Pubitemid 30185469)
72. Mine T, Shimizu H, Hiromoto K, et al. Beat-to-beat QT interval variability is primarily affected by the autonomic nervous system. Ann Noninvasive Electrocardiol 2008;13:228-33. (Pubitemid 351989362)
73. Brembilla-Perrot B, Spatz F, Khaldi E, et al. Value of esophageal pacing in evaluation of supraventricular tachycardia. Am J Cardiol 1990;65:322-30.
74. Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: a diagnostic and therapeutic tool. Circulation 1982;65:336-41. (Pubitemid 12219028)
75. Blomstrom-Lundqvist C, Dohnal M, Hirsch I, et al. Effect of long term treatment with metoprolol and sotalol on ventricular repolarisation measured by use of transoesophageal atrial pacing. Br Heart J 1986;55:181-6. (Pubitemid 16130028)
76. Darpo B, Vallin H, Almgren O, et al. Selective Ik blocker almokalant exhibits class III-specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings. J Cardiovasc Pharmacol 1995;26:530-40.
77. Marchant B. QT prolongation associated with vasodilatation. Presentation at the DIA meeting in Barcelona, Spain; 2008.
78. Demolis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996;94:1592-9. (Pubitemid 26320263)
79. Demolis JL, Charransol A, Funck-Brentano C, et al. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 1996;41:499-503. (Pubitemid 26184671)
80. Demolis JL, Martel C, Funck-Brentano C, et al. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol 1997;44:403-9. (Pubitemid 27402117)
81. Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658-66. (Pubitemid 32059992)
82. Demolis JL, Vacheron F, Cardus S, et al. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 2003;73:242-52. (Pubitemid 36269675)
83. Funck-Brentano C, Kibleur Y, Le CF, et al. Rate dependence of sotalolinduced prolongation of ventricular repolarization during exercise in humans. Circulation 1991;83:536-45.
84. Hulot JS, Demolis JL, Riviere R, et al. Influence of endogenous oestrogens on QT interval duration. Eur Heart J 2003;24:1663-7. (Pubitemid 37174906)
85. Florian JA, Tornoe CW, Brundage R, et al. Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 2011:1152-62.
86. Yan LK, Zhang J, Ng MJ, et al. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat 2010;20:497-507.
87. Frederiks J, Swenne CA, Kors JA, et al. Within-subject electrocardiographic differences at equal heart rates: role of the autonomic nervous system. Pflugers Arch 2001;441:717-24. (Pubitemid 32182086)